Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. JANX
stocks logo

JANX

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
650.00K
-48.08%
--
--
300.00K
-96.63%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.76%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-7.76%
In Past 3 Month
10 Analyst Rating
up Image0
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 76.57 USD with a low forecast of 36.00 USD and a high forecast of 100.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
up Image0
Current: 27.027
sliders
Low
36.00
Averages
76.57
High
100.00
up Image0
Current: 27.027
sliders
Low
36.00
Averages
76.57
High
100.00
Raymond James
Sean McCutcheon
Outperform
initiated
$65
2025-07-11
Reason
Raymond James
Sean McCutcheon
Price Target
$65
2025-07-11
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon initiated coverage of Janux Therapeutics with an Outperform rating and $65 price target. Janux is clinical-stage company focused on developing masked T-cell engagers for several cancer types, the analyst tells investors in a research note. The firm sees good results to date for JANX007, saying the data offer "strong proof-of-concept" for the masking technology employed by Janux.
Scotiabank
Sector Perform
downgrade
$41 -> $36
2025-05-09
Reason
Scotiabank
Price Target
$41 -> $36
2025-05-09
downgrade
Sector Perform
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$70
2025-03-03
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$70
2025-03-03
Reiterates
Strong Buy
Reason
Scotiabank
George Farmer
Hold
Maintains
$62 → $41
2025-02-28
Reason
Scotiabank
George Farmer
Price Target
$62 → $41
2025-02-28
Maintains
Hold
Reason
Cantor Fitzgerald
Josh Schimmer
Buy
Reiterates
$200
2024-12-11
Reason
Cantor Fitzgerald
Josh Schimmer
Price Target
$200
2024-12-11
Reiterates
Buy
Reason
Scotiabank
George Farmer
Hold
Maintains
$42 → $62
2024-12-04
Reason
Scotiabank
George Farmer
Price Target
$42 → $62
2024-12-04
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Janux Therapeutics Inc (JANX.O) is -11.67, compared to its 5-year average forward P/E of -16.22. For a more detailed relative valuation and DCF analysis to assess Janux Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.22
Current PE
-11.67
Overvalued PE
-4.81
Undervalued PE
-27.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.75
Current EV/EBITDA
-3.54
Overvalued EV/EBITDA
0.14
Undervalued EV/EBITDA
-17.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
474.32
Current PS
1059.02
Overvalued PS
896.57
Undervalued PS
52.06

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 575.67% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

JANX News & Events

Events Timeline

(ET)
2025-05-15
08:06:34
Janux appoints Janeen Doyle chief corporate, business development officer
select
2025-05-08 (ET)
2025-05-08
16:05:01
Janux Therapeutics reports Q1 EPS (38c), consensus (39c)
select
2025-05-05 (ET)
2025-05-05
09:18:19
Janux Therapeutics initiates expansion studies in ENGAGER-PSMA-01 trial
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-12Benzinga
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

  • Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, including KALA Bio with a Buy rating and a price target of $12, James Hardie Industries with an Outperform rating and a price target of $32, and Harrow, Inc. with an Overweight rating and a price target of $76.

  • Stock Performance Overview: The current stock prices for these companies are as follows: KALA at $6.90, JHX at $28.27, HROW at $31.37, JANX at $25.61, and SOFI at $20.97, reflecting varying market sentiments and analyst expectations.

Preview
2.0
06-19NASDAQ.COM
Janux Therapeutics Becomes Oversold (JANX)

  • Stock Performance: Janux Therapeutics Inc (JANX) shares have entered oversold territory with an RSI of 29.6, indicating potential exhaustion of recent selling pressure as the stock trades around $22.72, close to its 52-week low of $22.48.

  • Market Comparison: In contrast, the S&P 500 ETF (SPY) has a higher RSI of 59.3, suggesting that while JANX may present buying opportunities, broader market conditions remain stronger.

Preview
9.0
05-05Newsfilter
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

  • Phase 1b Expansion Study: Janux Therapeutics has initiated a Phase 1b expansion study for JANX007 in taxane-naïve patients with metastatic castration-resistant prostate cancer (mCRPC), following positive interim results from the Phase 1a dose escalation trial.

  • Future Developments: Additional studies are planned to evaluate JANX007 in various patient populations, and updates on JANX007 and another candidate, JANX008, are expected in the second half of 2025, alongside an R&D Day showcasing preclinical pipeline advancements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Janux Therapeutics Inc (JANX) stock price today?

The current price of JANX is 27.0272 USD — it has decreased -2.61 % in the last trading day.

arrow icon

What is Janux Therapeutics Inc (JANX)'s business?

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

arrow icon

What is the price predicton of JANX Stock?

Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 76.57 USD with a low forecast of 36.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Janux Therapeutics Inc (JANX)'s revenue for the last quarter?

Janux Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Janux Therapeutics Inc (JANX)'s earnings per share (EPS) for the last quarter?

Janux Therapeutics Inc. EPS for the last quarter amounts to -0.38 USD, increased 26.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Janux Therapeutics Inc (JANX)'s fundamentals?

The market is revising No Change the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -7.76%.
arrow icon

How many employees does Janux Therapeutics Inc (JANX). have?

Janux Therapeutics Inc (JANX) has 74 emplpoyees as of July 18 2025.

arrow icon

What is Janux Therapeutics Inc (JANX) market cap?

Today JANX has the market capitalization of 1.64B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free